| Literature DB >> 18364995 |
X Riera1, V Moreno, C J Ciudad, V Noe, M Font-Bardía, X Solans.
Abstract
Four new metal complexes {M =Entities:
Year: 2007 PMID: 18364995 PMCID: PMC2266976 DOI: 10.1155/2007/98732
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Schematic representation of the two tautomeric forms of the 9-aminoacridine.
Scheme 2Scheme of the synthesis of the complexes (a) [Pd(9AA)(μ-Cl)]2 and [Pt(9AA)(L)] (L = py- d 5 or PPh3) and (b) [Pt(9AA)Cl(DMSO)]: *De SiO2. The eluted used was a mixture CHCl3:DMF (100:50).
1H chemical shifts (ppm) of 9-aminoacridine (9AA) and the complexes [Pd(9AA)(μ-Cl)]2 ⋅ 2DMF, [Pd(9AA)Cl(L)] (L = py-d 5 or PPh3) and [Pt(9AA)Cl(DMSO)]. The numbering corresponds to the attached scheme and it will be the same along the spectroscopic studies.
| 9AA | [Pd(9AA)(μCl)]& 2 | [Pd(9AA)Cl(py- | [Pd(9AA)Cl(PPh3)]& | [Pt(9AA)Cl(DMSO)]$ | |
|---|---|---|---|---|---|
| H1 | 8.40 d | — | — | — | — |
| H2 | 7.65 t | 7.71 d | 5.89 d | 6.04 dd | 7.95 d |
| H3 | 7.32 t | 7.37 t | 7.19 t | 6.75 t | 7.39 t |
| H4 | 7.80 d | 7.14 d | 7.11 d | 6.88 d | 7.12 d |
| H5 | 7.80 d | 7.53 d | 7.59 d | 7.48 | 7.62 d |
| H6 | 7.32 t | 7.74 t | 7.71 t | 7.62 | 7.76 t |
| H7 | 7.65 t | 7.23 t | 7.25 t | 7.22 t | 7.34 t |
| H8 | 8.40 d | 8.66 d | 8.60 d | 8.64 d | 8.66 d |
| NH9 | — | 8.94 s | 8.78 w | 9.08 d | 8.58 w |
| NH10 | — | 11.65 s | 11.68 w | 11.42 s | 10.73 w |
s: singlet, d: doublet, t: triplet, w: wide, dd: doublet of doublets.
&DMF signals were assigned at 7.99, 2.89 and 2.30 ppm.
#Pyridine- d 5 signals were assigned at 7.40 and 7.80 ppm.
$Recorded in acetone- d 6. The spectrum shows an additional singlet at 3.49 ppm assigned to the protons of the CH3 groups of DMSO (3 J Pt-H(DMSO) = 21 Hz).
Figure 21H–13C bidimensional heterocorrelated NMR spectrum of the compound [Pd(9AA)(μ-Cl)]2 (aromatic zone) where seven peaks of crossover are observed as indicator of the presence of a σ (M–Csp2, aryl) bond.
Figure 11H NMR spectrum (zone 6–11.5ppm) of the complex [Pd(9AA)Cl(PPh3)]. *Signal assigned to the DMF present in the precursor complex [Pd(9AA)(μ-Cl2)] ⋅ 2DMF.
Figure 31H NMR spectrum of the complex [Pt(9AA)Cl(DMSO)].
Crystal data and structure refinement for [Pd(9AA)(μ-Cl)]2 ⋅ 2DMF.
| Empirical formula | C26H30Cl2N8Pd2 |
| Formula weight | 738.28 |
| Crystal size (mm) | 0.1 × 0.1 × 0.2 |
| Crystal system | Monoclinic |
| Space group | P21 /c |
| a, b, c (′) | a = 12.421(6) b = 9.538(5) c = 14.476(14) |
|
|
|
| Volume (Å3) | 1620.9(19) |
| Z | 1 |
| Density (calc.) (Mg × m−3) | 0.756 |
| Absorption coefficient (mm−1) | 0.651 |
| F(000) | 368 |
| Temperature (K) | 293(2) |
| Wavelength (′) | 0.71069 |
|
| 2.60–29.97 |
| Reflexions collected | 4911 |
| Unique reflexions | 4715 [R(int) = 0.0182] |
| Data/restraints/parameters | 4665/0/200 |
| Goodness-of-fit on F2 | 1.007 |
| Final R | R1 = 0.0336, wR1 = 0.0895 |
| R (all data) | R1 = 0.0507, wR2 = 0.0968 |
Figure 4Molecular structure of the complex [Pd(9AA)(μ-Cl)]2 ⋅ 2DMF.
Figure 5Geometry of the fragment “Pd(μ-X)2 Pd” and dependence of the distance Pd ⋯ Pd with the angle Φ.
Figure 6DC spectra of Calf Thymus DNA incubated with (a) 9-aminoacridine (9AA), (b) [Pd(9AA)(μ-Cl)]2, and (c) [Pt(9AA)Cl(DMSO)].
Ellipticity values and wavelenghts (maximum and minimum) in CD spectra of Calf Thymus DNA incubated with 9-aminoacridine (9AA) and its palladium and platinum complexes.
| Compound | ri |
|
|
|
| % uptaken metal |
|---|---|---|---|---|---|---|
| DNA(c) | — | 9.0 | 275.0 | −9.5 | 245.5 | — |
|
| ||||||
| 9AA | 0.01 | 9.8 | 274.1 | −10.9 | 246.0 | — |
|
| ||||||
| 0.10 | 15.3 | 270.0 | −15.9 | 247.0 | — | |
| 0.25 | 22.7 | 269.2 | −22.1 | 247.0 | — | |
| 0.50 | 30.0 | 268.8 | −26.5 | 247.8 | — | |
|
| ||||||
| [Pd(9AA)( | 0.01 | 8.8 | 274.5 | −10.1 | 245.8 | 62.24 |
|
| ||||||
| 0.10 | 7.8 | 274.4 | −9.8 | 244.8 | 51.82 | |
| 0.25 | 5.7 | 277.6 | −7.4 | 247.0 | 50.48 | |
| 0.50 | 2.4 | 282.4 | −3.7 | 250.0 | 52.67 | |
|
| ||||||
| DNA(d) | — | 6.6 | 276.0 | −7.9 | 245.0 | — |
|
| ||||||
| [Pt(9AA)Cl(DMSO)] | 0.01 | 6.6 | 276.0 | −8.1 | 245.6 | 9.72 |
|
| ||||||
| 0.10 | 6.7 | 272.8 | −7.7 | 245.8 | 7.43 | |
| 0.25 | 6.7 | 272.5 | −6.0 | 246.5 | 6.21 | |
| 0.50 | 6.2 | 273.8 | − | 247.1 | 5.44 | |
(a)degrees × cm2 × dmol−1 × 103;
(b)nm;
(c)6.49 × 10−5 mol × l−1;
(d)6.10 ×10−5 mol × l−1.
Figure 7Eletrophoretic mobility pattern of pBR322 plasmid DNA incubated with the complexes: lane A: cisplatin; lane B: [Pd(9AA)(μ-Cl)]2; lane C: 9AA.
Figure 8Electrophoretic mobility pattern of pBR322 plasmid DNA incubated with the complexes: lane A: cisplatin; lane B: [Pt(9AA)Cl(DMSO)].
Figure 9AFM image of the pBR322 plasmid DNA incubated with the complex [Pd(9AA)(μ-Cl)]2.
Figure 10Two AFM images corresponding to pBR322 plasmid DNA incubated with the complex [Pd(9AA)Cl(PPh3)].
IC50 values (μM) for the compounds studied against the tumor cell lines MCF-7, DU-145, and HeLa.
| Compound | MCF-7 | DU-145 | HeLa |
|---|---|---|---|
| cisplatin | 9.4 | 3.7 | 22.2 |
| 9AA | 4.9 | 11.9 | 22.2 |
| [Pd(9AA)( | 38.1 | 32.6 | >50 |